The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sivertseva S.A.

AO MSCH «Neftyanik»;
Ural State Medical University;
Kirov State Medical University

Prilenskaya A.M.

AO MSCH «Neftyanik»

Popova E.V.

City Clinical Hospital No. 24 of Moscow;
Pirogov Russian National Research University

Turova E.L.

Sverdlovsk Regional Clinical Hospital No. 1

Volkova L.I.

Ural State Medical University;
Sverdlovsk Regional Clinical Hospital No. 1

Smagina I.V.

Altai State Medical University;
Regional Clinical Hospital

Elchaninova E.Yu.

Altai State Medical University

Afanas’eva A.I.

Altai State Medical University

Goncharova Z.A.

Rostov State Medical University

Markova E.A.

Rostov State Medical University

Yarosh N.M.

Rostov State Medical University

Bakhtiyarova K.Z.

Bashkir State Medical University

Sherman M.A.

Kirov State Medical University

Boyko A.N.

Pirogov Russian National Research University;
Federal Center of Brain and Neurotechnologies

Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population

Authors:

Sivertseva S.A., Prilenskaya A.M., Popova E.V., Turova E.L., Volkova L.I., Smagina I.V., Elchaninova E.Yu., Afanas’eva A.I., Goncharova Z.A., Markova E.A., Yarosh N.M., Bakhtiyarova K.Z., Sherman M.A., Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9): 76‑82

DOI: 10.17116/jnevro202312309176

Read: 1408 times

Download PDF (RU)
Contact the author
Table of contents

ASSESSMENT OF THE EFFICACY AND SAFETY OF ALEMTUZUMAB IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIAN POPULATION
ASSESSMENT OF THE EFFICACY AND SAFETY OF ALEMTUZUMAB IN PATIENTS WITH HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIAN POPULATION

To cite this article:

Sivertseva SA, Prilenskaya AM, Popova EV, et al. Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9):76‑82. (In Russ.)
https://doi.org/10.17116/jnevro202312309176

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
Resu­lts of 4 years of therapy with divo­zilimab in patients with rela­psing multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):51-59
Abstract:

OBJECTIVE

To evaluate the severity and frequency of infusion reactions (IR) in patients with highly active relapsing-remitting multiple sclerosis (MS) In Russian population receiving alemtuzumab therapy.

MATERIAL AND METHODS

In retrospective study, we analyzed data from 50 patients with highly active relapsing-remitting multiple sclerosis (MS) from six Regional MS Centers in the Russian Federation who received two courses of alemtuzumab between 2018 and 2022.

RESULTS

Among all IRs, the most frequently reported were hives-like rashes, which were registered in 27 people, mostly of mild severity (70.6%). Headaches were the second most common IR, observed in 17 patients (34%). When comparing the group of patients who underwent music therapy (MT) with those who received alemtuzumab therapy without MT, no statistically significant difference was found in the frequency and severity of IRs.

CONCLUSION

All patients experienced IRs of varying degrees of severity. A decrease in the score on the EDSS disability scale was noted. MT did not affect the occurrence or severity of IRs.

Keywords:

alemtuzumab
multiple sclerosis
music therapy
infusion reactions

Authors:

Sivertseva S.A.

AO MSCH «Neftyanik»;
Ural State Medical University;
Kirov State Medical University

Prilenskaya A.M.

AO MSCH «Neftyanik»

Popova E.V.

City Clinical Hospital No. 24 of Moscow;
Pirogov Russian National Research University

Turova E.L.

Sverdlovsk Regional Clinical Hospital No. 1

Volkova L.I.

Ural State Medical University;
Sverdlovsk Regional Clinical Hospital No. 1

Smagina I.V.

Altai State Medical University;
Regional Clinical Hospital

Elchaninova E.Yu.

Altai State Medical University

Afanas’eva A.I.

Altai State Medical University

Goncharova Z.A.

Rostov State Medical University

Markova E.A.

Rostov State Medical University

Yarosh N.M.

Rostov State Medical University

Bakhtiyarova K.Z.

Bashkir State Medical University

Sherman M.A.

Kirov State Medical University

Boyko A.N.

Pirogov Russian National Research University;
Federal Center of Brain and Neurotechnologies

Received:

03.07.2023

Accepted:

04.08.2023

Close metadata

References:

  1. Steingo B, Malik YAl, Bass AD, et al. Long-term efficacy of alemtuzumab in patients with RRMS: 12-years follow-up of CAMMS223. J Neurol. 2020;44(2):56-59.  https://doi.org/10.1007/s00415-020-09983-1
  2. Syed YY. Alemtuzumab: A review in Relapsing Remitting Multiple Sclerosis. J Neurol. 2020;52(6):34-39.  https://doi.org/10.1007/s40265-020-01437-2
  3. Vukusic S, Brassat D, Seze J, et al. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD). Mult Scler Rel Dis. 2019;34(7):45-49.  https://doi.org/10.1016/j.msard.2019.01.019
  4. Frau J, Coghe G, Lorefice L, et al. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. J Neurol. 2020;4(2):56-59.  https://doi.org/10.1007/s00415-019-09272-6
  5. Pauli F, Riedl K, Hegen H, et al. Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication — a retrospective multicenter study. Mult Scler Rel Dis. 2022;34(6):38-42.  https://doi.org/10.1016/j.msard.2022.103810
  6. Alnahdi MA, Aljarba SI, Malir Y. Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anemia, alveolar haemorrhage, nephropathy, and stroke: a case report. Mult Scler Rel Dis. 2020;28(3):23-28.  https://doi.org/10.1016/j.msard.2020.102141
  7. Rauma I, Mustonen T, Seppa J, et al. Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients. J Neurol. 2021;56(6):56-61.  https://doi.org/10.1007/s00415-021-10664-w
  8. Rauber S, Pawlitzki M, Korsen M, et al. A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab. Mult Scler Rel Dis. 2022;23(6):23-27.  https://doi.org/10.1016/j.msard.2022.103670
  9. Leckey R, Borsellino L, Rawlings A, et al. Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen. Mult Scler Rel Dis. 2022;23(6):32-40.  https://doi.org/10.1016/j.msard.2022.104030
  10. Alroughani R, AlMojel M, Al-Hashel J, Ahmed SF. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwail’s experience. Mult Scler Rel Dis. 2023;28(2):35-41.  https://doi.org/10.1016/j.msard.2020.102141
  11. Bonitto J, Ayala O, Botero L. Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia. Mult Scler Rel Dis. 2022;22(4):18-23.  https://doi.org/10.1016/j.msard.2022.103780
  12. Herman JA, Khalighinejad F, York K, et al. A Real-World Cohort Analysis of Alemtuzumab Outcomes in Relapsing Multiple Sclerosis. Mult Scler Rel Dis. 2020;21(4):19-26.  https://doi.org/10.1016/j.msard.2020.102619
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.